Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2013 Filed Jan 29, 2013 21:46 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 5,639 | $53.21 | $300,051.19 |
DisclosureSEC source: 0001209191-13-004989 · doc4.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,207 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,107 Underlying: Common Stock · 14,107 shares Expires 2014-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,657 | $53.21 | $88,168.97 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 6,218 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:47 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 24,594 | $53.21 | $1,308,646.74 |
DisclosureSEC source: 0001209191-13-004991 · doc4.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,214 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:48 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 7,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-004993 · doc4.xml · derivative · entry 3 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,837 Underlying: Common Stock · 7,837 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:48 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantCommon Stock | 16,165 | $53.21 | $860,139.65 |
DisclosureSEC source: 0001209191-13-004993 · doc4.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,569 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:53 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GrantCommon Stock | 11,174 | $53.21 | $594,568.54 |
DisclosureSEC source: 0001209191-13-004998 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,941 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:54 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantRestricted Stock Unit · Derivative | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-004999 · doc4.xml · derivative · entry 4 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,405 Underlying: Common Stock · 9,405 shares Expires 2014-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:54 UTC |
Tapiero JacquesSVP&Pres., Emerging Markets
|
GrantCommon Stock | 19,733 | $53.21 | $1,049,992.93 |
DisclosureSEC source: 0001209191-13-004999 · doc4.xml · nonDerivative · entry 1 Tapiero Jacques · CIK 0001479078 · SVP&Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,334 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:56 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 9,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005004 · doc4.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,405 Underlying: Common Stock · 9,405 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:56 UTC |
Simmons Jeffrey NSVP&Pres.,Elanco Animal Health
|
GrantCommon Stock | 19,735 | $53.21 | $1,050,099.35 |
DisclosureSEC source: 0001209191-13-005004 · doc4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres.,Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,917 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:58 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 3,881 | $53.21 | $206,508.01 |
DisclosureSEC source: 0001209191-13-005005 · doc4.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,769 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:58 UTC |
Walsh Fionnuala MSVP, Global Quality
|
GrantCommon Stock | 13,924 | $53.21 | $740,896.04 |
DisclosureSEC source: 0001209191-13-005005 · doc4.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,307 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:59 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 1,300 | $53.21 | $69,173.00 |
DisclosureSEC source: 0001209191-13-005006 · doc4.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:00 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005008 · doc4.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,674 Underlying: Common Stock · 15,674 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:00 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 33,017 | $53.21 | $1,756,834.57 |
DisclosureSEC source: 0001209191-13-005008 · doc4.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,029 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GrantRestricted Stock Unit · Derivative | 58,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005012 · doc4.xml · derivative · entry 6 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,778 Underlying: Common Stock · 58,778 shares Expires 2014-02-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GrantCommon Stock | 129,075 | $53.21 | $6,868,080.75 |
DisclosureSEC source: 0001209191-13-005012 · doc4.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,856 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:04 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005015 · doc4.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,552 Underlying: Common Stock · 21,552 shares Expires 2014-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:04 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantCommon Stock | 44,832 | $53.21 | $2,385,510.72 |
DisclosureSEC source: 0001209191-13-005015 · doc4.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,179 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:06 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantRestricted Stock Unit · Derivative | 29,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-005018 · doc4.xml · derivative · entry 5 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,781 Underlying: Common Stock · 29,781 shares Expires 2014-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 22:06 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantCommon Stock | 53,845 | $53.21 | $2,865,092.45 |
DisclosureSEC source: 0001209191-13-005018 · doc4.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,845 Read SEC document |
| December 12, 2012 Filed Feb 4, 2013 21:36 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 1,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006004 · doc5.xml · nonDerivative · entry 10 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 52,042 F1 · ownership.nature: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 12, 2012 Filed Feb 4, 2013 21:36 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 1,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006004 · doc5.xml · nonDerivative · entry 8 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,781 Read SEC document |
| December 12, 2012 Filed Feb 4, 2013 21:38 UTC |
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
|
GiftCommon Stock | 289 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006007 · doc5.xml · nonDerivative · entry 1 Nobles Anne · CIK 0001462543 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,247 Read SEC document |
| December 05, 2012 Filed Feb 4, 2013 21:36 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 640 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006004 · doc5.xml · nonDerivative · entry 12 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The John C. Lechleiter Spouse and Descendants Trust dtd 11/1/12 Disclosed balance after: 72,140 F2 · ownership.nature: Irrevocable trust for the benefit of reporting person's spouse and children. Spouse is trustee. Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2012 Filed Feb 4, 2013 21:36 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 640 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006004 · doc5.xml · nonDerivative · entry 7 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,825 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:26 UTC |
Zakrowski Donald AChief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,641 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055851 · doc4.xml · derivative · entry 4 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,641 shares Expires 2012-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:26 UTC |
Zakrowski Donald AChief Accounting Officer
|
Tax withholdingCommon Stock | 517 | $49.04 | $25,353.68 |
DisclosureSEC source: 0001209191-12-055851 · doc4.xml · nonDerivative · entry 2 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:26 UTC |
Zakrowski Donald AChief Accounting Officer
|
Exercise / conversionCommon Stock | 1,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055851 · doc4.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:30 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,778 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055854 · doc4.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,778 shares Expires 2012-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:30 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 1,166 | $49.04 | $57,180.64 |
DisclosureSEC source: 0001209191-12-055854 · doc4.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,645 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:30 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 3,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055854 · doc4.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,748 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,748 shares Expires 2012-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
Tax withholdingCommon Stock | 865 | $49.04 | $42,419.60 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,767 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
Exercise / conversionCommon Stock | 2,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 18:55 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055254 · doc4.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,427 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 18:57 UTC |
Baicker KatherineDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055259 · doc4.xml · nonDerivative · entry 1 Baicker Katherine · CIK 0001537067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,083 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:01 UTC |
BISCHOFF WINFRIED F W SIRDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055263 · doc4.xml · nonDerivative · entry 1 BISCHOFF WINFRIED F W SIR · CIK 0001196150 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,253 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:05 UTC |
ESKEW MICHAEL LDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055268 · doc4.xml · nonDerivative · entry 1 ESKEW MICHAEL L · CIK 0001227734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,937 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:08 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055270 · doc4.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,997 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:12 UTC |
GILMAN ALFRED GDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055273 · doc4.xml · nonDerivative · entry 1 GILMAN ALFRED G · CIK 0001225473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,808 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:15 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055275 · doc4.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,486 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:21 UTC |
HORN KAREN NDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055278 · doc4.xml · nonDerivative · entry 1 HORN KAREN N · CIK 0001136550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,103 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:22 UTC |
Kaelin William G JrDirector
|
GrantCommon Stock | 1,798 | $47.03 | $84,559.94 |
DisclosureSEC source: 0001209191-12-055283 · doc4.xml · nonDerivative · entry 1 Kaelin William G Jr · CIK 0001551715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,798 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:27 UTC |
MARRAM ELLEN RDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055285 · doc4.xml · nonDerivative · entry 1 MARRAM ELLEN R · CIK 0001234124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,167 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:38 UTC |
OBERHELMAN DOUGLAS RDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055289 · doc4.xml · nonDerivative · entry 1 OBERHELMAN DOUGLAS R · CIK 0001171770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,427 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:42 UTC |
PRENDERGAST FRANKLYN GDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055294 · doc4.xml · nonDerivative · entry 1 PRENDERGAST FRANKLYN G · CIK 0001233256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,003 Read SEC document |
| November 30, 2012 Filed Dec 3, 2012 19:46 UTC |
SEIFERT KATHI PDirector
|
GrantCommon Stock | 3,083 | $47.03 | $144,993.49 |
DisclosureSEC source: 0001209191-12-055298 · doc4.xml · nonDerivative · entry 1 SEIFERT KATHI P · CIK 0001222893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,480 Read SEC document |
| November 29, 2012 Filed Feb 4, 2013 21:36 UTC |
LECHLEITER JOHN CDirector · Chairman, President, and CEO
|
GiftCommon Stock | 71,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-13-006004 · doc5.xml · nonDerivative · entry 11 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President, and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The John C. Lechleiter Spouse and Descendants Trust dtd 11/1/12 Disclosed balance after: 71,500 F2 · ownership.nature: Irrevocable trust for the benefit of reporting person's spouse and children. Spouse is trustee. Reporting person disclaims beneficial ownership of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.